Board of Directors
Anatoly Dritschilo, MD, FACR
Anatoly Dritschilo, MD, FACR
Anatoly Dritschilo, MD, FACR
Our leadership is uniquely positioned to deliver on the promise of PSMA-targeted diagnostics and therapeutics to advance a transformative approach to prostate cancer management. With decades of experience and a collaborative team of scientists and advisors, our goal is to develop the next generation of PSMA-targeted therapies. If you have
Our leadership is uniquely positioned to deliver on the promise of PSMA-targeted diagnostics and therapeutics to advance a transformative approach to prostate cancer management. With decades of experience and a collaborative team of scientists and advisors, our goal is to develop the next generation of PSMA-targeted therapies. If you have any questions or want to learn more, feel free to contact us, as we believe that health matters. The team combines administrative, scientific, and clinical experts united in our mission to advance innovative diagnostics and therapeutics to improve outcomes of prostate cancer treatment.
Alan Kozikowski, Ph.D.
Anatoly Dritschilo, MD, FACR
Anatoly Dritschilo, MD, FACR
Chief Science Officer & Member BOD. For any inquiries related to health matters, please feel free to contact us.
Emer Leahy, Ph.D.
Chris Senanayake, Ph.D.
Chris Senanayake, Ph.D.
For inquiries related to health matters or to connect with our Member BOD, please feel free to contact us.
Chris Senanayake, Ph.D.
Chris Senanayake, Ph.D.
Chris Senanayake, Ph.D.
For inquiries related to health matters or to connect with our Member BOD, please feel free to contact us.
Scientific Advisors
Joseph Armstrong, Ph.D.
Werner Tueckmantel, Ph.D.
Wayne William Hancock, MB.BS, Ph.D., FRCPA
